Omer Sager1, Ferrat Dincoglan2, Bora Uysal2, Selcuk Demiral2, Hakan Gamsiz2, Yelda Elcim2, Esin Gundem2, Bahar Dirican2, Murat Beyzadeoglu2. 1. Department of Radiation Oncology, Gulhane Medical Faculty, University of Health Sciences, Gn.TevfikSaglam Cad., Etlik, 06018, Kecioren, Ankara, Turkey. omersager@gmail.com. 2. Department of Radiation Oncology, Gulhane Medical Faculty, University of Health Sciences, Gn.TevfikSaglam Cad., Etlik, 06018, Kecioren, Ankara, Turkey.
Abstract
PURPOSE: The aim of this study is to evaluate adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma. MATERIALS AND METHODS: Forty-eight patients with clinically evident seroma at the time of planning CT simulation for WBI were included. Two RT treatment plannings were generated for each patient based on the initial CT simulation and tumor bed boost CT simulation to assess seroma and boost target volume (BTV) changes during WBI. Also, dosimetric impact of ART was analyzed by comparative evaluation of critical organ doses in both RT treatment plannings. RESULTS: Median time interval between the two CT simulations was 35 days. Statistically significant reduction was detected in seroma volume and BTV during the conventionally fractionated WBI course along with statistically significant reduction in critical organ doses with ART (p < 0.0001). CONCLUSION: Our data suggest significant benefit of ART by use of replanning the tumor bed boost with repeated CT simulation after WBI for patients with clinically evident seroma.
PURPOSE: The aim of this study is to evaluate adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancerpatients having clinically evident seroma. MATERIALS AND METHODS: Forty-eight patients with clinically evident seroma at the time of planning CT simulation for WBI were included. Two RT treatment plannings were generated for each patient based on the initial CT simulation and tumor bed boost CT simulation to assess seroma and boost target volume (BTV) changes during WBI. Also, dosimetric impact of ART was analyzed by comparative evaluation of critical organ doses in both RT treatment plannings. RESULTS: Median time interval between the two CT simulations was 35 days. Statistically significant reduction was detected in seroma volume and BTV during the conventionally fractionated WBI course along with statistically significant reduction in critical organ doses with ART (p < 0.0001). CONCLUSION: Our data suggest significant benefit of ART by use of replanning the tumor bed boost with repeated CT simulation after WBI for patients with clinically evident seroma.
Entities:
Keywords:
Adaptive radiotherapy (ART); Breast cancer; Seroma; Tumor bed boost; Whole breast irradiation (WBI)
Authors: Tanja Alderliesten; Suzanne den Hollander; Tzu-I Jonathan Yang; Paula H M Elkhuizen; Anke M van Mourik; Coen Hurkmans; Peter Remeijer; Corine van Vliet-Vroegindeweij Journal: Radiother Oncol Date: 2011-04-16 Impact factor: 6.280
Authors: Brendan Prendergast; Daniel J Indelicato; Stephen R Grobmyer; Anneyuko I Saito; Judith L Lightsey; Felicia E Snead; Christopher G Morris; Edward M Copeland; Nancy P Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2009-01-23 Impact factor: 7.038
Authors: C Vrieling; L Collette; A Fourquet; W J Hoogenraad; J C Horiot; J J Jager; M Pierart; P M Poortmans; H Struikmans; M Van der Hulst; E Van der Schueren; H Bartelink Journal: Int J Radiat Oncol Biol Phys Date: 1999-10-01 Impact factor: 7.038
Authors: Kevin S Oh; Feng-Ming Kong; Kent A Griffith; Beth Yanke; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-25 Impact factor: 7.038
Authors: Philip M Poortmans; Laurence Collette; Jean-Claude Horiot; Walter F Van den Bogaert; Alain Fourquet; Abraham Kuten; Evert M Noordijk; Willem Hoogenraad; René-Olivier Mirimanoff; Marianne Pierart; Erik Van Limbergen; Harry Bartelink Journal: Radiother Oncol Date: 2008-08-15 Impact factor: 6.280